Condition: Allergic Rhinitis
Interventions: Drug: 205.5 mcg of azelastine hydrochloride; Drug: 137 mcg of azelastine hydrochloride
Sponsors: Meda Pharmaceuticals; Meda Pharmaceuticals; Novella Clinical Research
Recruiting – verified June 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days